INSMED INC (INSM)

US4576693075 - Common Stock

27.075  -0.25 (-0.9%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to INSM. INSM was compared to 592 industry peers in the Biotechnology industry. Both the profitability and financial health of INSM have multiple concerns. While showing a medium growth rate, INSM is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

In the past year INSM has reported negative net income.
INSM had a negative operating cash flow in the past year.
In the past 5 years INSM always reported negative net income.
In the past 5 years INSM always reported negative operating cash flow.

1.2 Ratios

INSM has a Return On Assets (-56.36%) which is in line with its industry peers.
Industry RankSector Rank
ROA -56.36%
ROE N/A
ROIC N/A
ROA(3y)-40.13%
ROA(5y)-38.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

INSM has a Gross Margin of 78.52%. This is amongst the best in the industry. INSM outperforms 86.56% of its industry peers.
INSM's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for INSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y0.78%

3

2. Health

2.1 Basic Checks

INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INSM has more shares outstanding
INSM has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, INSM has a worse debt to assets ratio.

2.2 Solvency

INSM has an Altman-Z score of -2.99. This is a bad value and indicates that INSM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INSM (-2.99) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.99
ROIC/WACCN/A
WACC8.38%

2.3 Liquidity

INSM has a Current Ratio of 4.12. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
INSM has a Current ratio (4.12) which is in line with its industry peers.
A Quick Ratio of 3.75 indicates that INSM has no problem at all paying its short term obligations.
INSM has a Quick ratio (3.75) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 3.75

6

3. Growth

3.1 Past

The earnings per share for INSM have decreased strongly by -36.92% in the last year.
The Revenue has grown by 24.39% in the past year. This is a very strong growth!
INSM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.92% yearly.
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-5.79%
Revenue 1Y (TTM)24.39%
Revenue growth 3Y22.9%
Revenue growth 5Y98.92%
Revenue growth Q2Q41.13%

3.2 Future

The Earnings Per Share is expected to grow by 17.56% on average over the next years. This is quite good.
The Revenue is expected to grow by 41.11% on average over the next years. This is a very strong growth
EPS Next Y13.08%
EPS Next 2Y13.7%
EPS Next 3Y15.9%
EPS Next 5Y17.56%
Revenue Next Year17.21%
Revenue Next 2Y31.18%
Revenue Next 3Y39.92%
Revenue Next 5Y41.11%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
Also next year INSM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

INSM's earnings are expected to grow with 15.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.7%
EPS Next 3Y15.9%

0

5. Dividend

5.1 Amount

No dividends for INSM!.
Industry RankSector Rank
Dividend Yield N/A

INSMED INC

NASDAQ:INSM (3/28/2024, 3:41:08 PM)

27.075

-0.25 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.02B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.36%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 78.52%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.12
Quick Ratio 3.75
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y13.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)24.39%
Revenue growth 3Y22.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y